Literature DB >> 33879449

RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease.

Amy C Mandigo1, Wei Yuan2,3, Kexin Xu4, Peter Gallagher1, Angel Pang5, Yi Fang Guan5, Ayesha A Shafi1, Chellappagounder Thangavel6,7,8, Beshara Sheehan2,3, Denisa Bogdan2,3, Alec Paschalis2,3, Jennifer J McCann1, Talya S Laufer1, Nicolas Gordon1, Irina A Vasilevskaya1, Emanuela Dylgjeri1, Saswati N Chand1, Matthew J Schiewer1, Josep Domingo-Domenech1, Robert B Den1,6,8, Jeff Holst7, Peter A McCue1,8, Johann S de Bono2,3, Christopher McNair1,8, Karen E Knudsen9,6,8.   

Abstract

Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming biological networks that drive cancer progression, although mechanistic insight has been largely limited to the impact of RB loss on cell-cycle regulation. Here, isogenic modeling of RB loss identified disease stage-specific rewiring of E2F1 function, providing the first-in-field mapping of the E2F1 cistrome and transcriptome after RB loss across disease progression. Biochemical and functional assessment using both in vitro and in vivo models identified an unexpected, prominent role for E2F1 in regulation of redox metabolism after RB loss, driving an increase in the synthesis of the antioxidant glutathione, specific to advanced disease. These E2F1-dependent events resulted in protection from reactive oxygen species in response to therapeutic intervention. On balance, these findings reveal novel pathways through which RB loss promotes cancer progression and highlight potentially new nodes of intervention for treating RB-deficient cancers. SIGNIFICANCE: This study identifies stage-specific consequences of RB loss across cancer progression that have a direct impact on tumor response to clinically utilized therapeutics. The study herein is the first to investigate the effect of RB loss on global metabolic regulation and link RB/E2F1 to redox control in multiple advanced diseases.This article is highlighted in the In This Issue feature, p. 2113. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33879449      PMCID: PMC8419081          DOI: 10.1158/2159-8290.CD-20-1114

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  73 in total

1.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

2.  Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.

Authors:  Qian Wang; Jessamy Tiffen; Charles G Bailey; Melanie L Lehman; William Ritchie; Ladan Fazli; Cynthia Metierre; Yue Julie Feng; Estelle Li; Martin Gleave; Grant Buchanan; Colleen C Nelson; John E J Rasko; Jeff Holst
Journal:  J Natl Cancer Inst       Date:  2013-09-19       Impact factor: 13.506

3.  A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis.

Authors:  Chen Huang; Zhengjun Qiu; Liwei Wang; Zhihai Peng; Zhiliang Jia; Craig D Logsdon; Xiangdong Le; Daoyan Wei; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2011-12-22       Impact factor: 12.701

4.  BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.

Authors:  David N Debruyne; Ruben Dries; Satyaki Sengupta; Davide Seruggia; Yang Gao; Bandana Sharma; Hao Huang; Lisa Moreau; Michael McLane; Daniel S Day; Eugenio Marco; Ting Chen; Nathanael S Gray; Kwok-Kin Wong; Stuart H Orkin; Guo-Cheng Yuan; Richard A Young; Rani E George
Journal:  Nature       Date:  2019-08-07       Impact factor: 49.962

Review 5.  Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.

Authors:  Karen E Knudsen; Trevor M Penning
Journal:  Trends Endocrinol Metab       Date:  2010-02-06       Impact factor: 12.015

6.  Regulation of the PDK4 isozyme by the Rb-E2F1 complex.

Authors:  Michael C F Hsieh; Debopriya Das; Nandakumar Sambandam; Michael Q Zhang; Zaher Nahlé
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

Review 7.  RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis.

Authors:  Riccardo Di Fiore; Antonella D'Anneo; Giovanni Tesoriere; Renza Vento
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

8.  Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas.

Authors:  M M Ittmann; R Wieczorek
Journal:  Hum Pathol       Date:  1996-01       Impact factor: 3.466

9.  Intragenic DNA methylation and BORIS-mediated cancer-specific splicing contribute to the Warburg effect.

Authors:  Smriti Singh; Sathiya Pandi Narayanan; Kajal Biswas; Amit Gupta; Neha Ahuja; Sandhya Yadav; Rajendra Kumar Panday; Atul Samaiya; Shyam K Sharan; Sanjeev Shukla
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-09       Impact factor: 11.205

Review 10.  Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer.

Authors:  Pranavi Koppula; Yilei Zhang; Li Zhuang; Boyi Gan
Journal:  Cancer Commun (Lond)       Date:  2018-04-25
View more
  11 in total

1.  KAT2A affects tumor metabolic reprogramming in colon cancer progression through epigenetic activation of E2F1.

Authors:  Xiaofeng Han; Jie Chen
Journal:  Hum Cell       Date:  2022-05-18       Impact factor: 4.174

2.  Knockout of ICAT in Adipose Tissue Alleviates Fibro-inflammation in Obese Mice.

Authors:  Zhuan Song; Ning Liu; Yu He; Jingqing Chen; Jun Li; Fengchao Wang; Zhenlong Wu
Journal:  Inflammation       Date:  2022-10-01       Impact factor: 4.657

3.  Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.

Authors:  Wanting Han; Mingyu Liu; Dong Han; Anthia A Toure; Muqing Li; Anna Besschetnova; Zifeng Wang; Susan Patalano; Jill A Macoska; Hung-Ming Lam; Eva Corey; Housheng Hansen He; Shuai Gao; Steven P Balk; Changmeng Cai
Journal:  Mol Ther       Date:  2022-02-02       Impact factor: 12.910

Review 4.  Advancing Cancer Treatment by Targeting Glutamine Metabolism-A Roadmap.

Authors:  Anna Halama; Karsten Suhre
Journal:  Cancers (Basel)       Date:  2022-01-22       Impact factor: 6.639

Review 5.  Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers.

Authors:  Kasey R Cargill; William L Hasken; Carl M Gay; Lauren A Byers
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

6.  RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.

Authors:  Chenkui Miao; Takuya Tsujino; Tomoaki Takai; Fu Gui; Takeshi Tsutsumi; Zsofia Sztupinszki; Zengjun Wang; Haruhito Azuma; Zoltan Szallasi; Kent W Mouw; Lee Zou; Adam S Kibel; Li Jia
Journal:  Sci Adv       Date:  2022-02-18       Impact factor: 14.136

7.  RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.

Authors:  Wanting Han; Mingyu Liu; Dong Han; Muqing Li; Anthia A Toure; Zifeng Wang; Anna Besschetnova; Susan Patalano; Jill A Macoska; Shuai Gao; Housheng Hansen He; Changmeng Cai
Journal:  Oncogene       Date:  2022-01-03       Impact factor: 8.756

Review 8.  Genes and Longevity of Lifespan.

Authors:  May Nasser Bin-Jumah; Muhammad Shahid Nadeem; Sadaf Jamal Gilani; Fahad A Al-Abbasi; Inam Ullah; Sami I Alzarea; Mohammed M Ghoneim; Sultan Alshehri; Aziz Uddin; Bibi Nazia Murtaza; Imran Kazmi
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

9.  The nociceptin receptor promotes autophagy through NF-kB signaling and is transcriptionally regulated by E2F1 in HCC.

Authors:  Xiaoshuang Zhou; Dongtai Chen; Yan Yan; Qiang Li; Wei Xing; Yanling Liu; Yonghua Chen; Dongyin Wang; Yunfei Yuan; Jingdun Xie; Weian Zeng; Jiahao Pan
Journal:  Cell Death Discov       Date:  2022-04-05

10.  Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.

Authors:  Blossom Mak; Hui-Ming Lin; Edmond M Kwan; Heidi Fettke; Ben Tran; Ian D Davis; Kate Mahon; Martin R Stockler; Karen Briscoe; Gavin Marx; Alison Zhang; Megan Crumbaker; Winston Tan; Kevin Huynh; Thomas G Meikle; Natalie A Mellett; Andrew J Hoy; Pan Du; Jianjun Yu; Shidong Jia; Anthony M Joshua; David J Waugh; Lisa M Butler; Manish Kohli; Peter J Meikle; Arun A Azad; Lisa G Horvath
Journal:  BMC Med       Date:  2022-03-25       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.